

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.


AIM Vaccine Co., Ltd.
艾美疫苗股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 06660)

NOTICE OF THE H SHARE CLASS MEETING

NOTICE IS HEREBY GIVEN THAT the 2023 third H share class meeting (the “**H Share Class Meeting**”) of AIM Vaccine Co., Ltd. (the “**Company**”) will be held on November 28, 2023, immediately after the conclusion or any adjourned meeting of the 2023 second extraordinary general meeting and the 2023 third class meeting for holders of domestic shares of the Company at Meeting Room, 43/F, Building 1, Lujiazui Century Financial Plaza, No. 729 Yanggao South Road, Pudong New District, Shanghai, the People’s Republic of China for the following purposes:

SPECIAL RESOLUTIONS

1. To consider and approve the resolution to change the existing registered office of the Company in the PRC to Room 412, 4/F, Building 6, No. 105 Jinghai 3rd Road, Beijing Economic-Technological Development Area, Beijing, and the relevant proposed amendments to the Articles of Association, and to authorize the directors of the Company to deal with on behalf of the Company the relevant application(s), approval(s), registration(s), filing(s) and other relevant procedures or issues and to make further amendment(s) (where necessary) pursuant to the requirements of the relevant governmental and/or regulatory authorities arising therefrom.
2. To consider and approve the resolution on the proposed amendments to the Articles of Association set out in Appendix II to the circular of the Company dated November 10, 2023.

By order of the Board
AIM Vaccine Co., Ltd.
Mr. Yan ZHOU

*Chairman of the Board of Directors,
executive Director and chief executive officer*

Hong Kong, November 10, 2023

Notes:

1. All resolutions at the H Share Class Meeting will be taken by poll (except where the chairman decides to allow a resolution relating to a procedural or administrative matter to be voted on by a show of hands) pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The results of the poll will be published on the websites of the Company at <https://www.aimbio.com> and Hong Kong Exchanges and Clearing Limited at www.hkexnews.hk after the H Share Class Meeting.
2. Any Shareholder entitled to attend and vote at the H Share Class Meeting convened by the above notice is entitled to appoint one or more proxies to attend and vote instead of him/her. A proxy needs not be a Shareholder of the Company.
3. In order to be valid, the instrument appointing a proxy together with the power of attorney or other authority, if any, under which it is signed, or a notarially certified copy of such power of attorney or authority, must be completed and returned to the H Share Registrar of the Company, Tricor Investor Services Limited at 17/F., Far East Finance Centre, 16 Harcourt Road, Hong Kong, at least 24 hours before the H Share Class Meeting (i.e. before 9:30 a.m. on November 27, 2023) or any adjourned meeting thereof. Completion and return of the form of proxy will not preclude a Shareholder from attending and voting at the H Share Class Meeting or any adjourned meeting thereof should he/she so wish.
4. For the purpose of determining the list of holders of H Shares who are entitled to attend the H Share Class Meeting, the H Share register of members of the Company will be closed from November 23, 2023 to November 28, 2023, both days inclusive, during which period no transfer of H Shares will be registered. In order to be eligible to attend and vote at the H Share Class Meeting, unregistered holders of the H Shares shall ensure all transfer documents accompanied by the relevant share certificates must be lodged with the Company's H Share Registrar, Tricor Investor Services Limited at 17/F., Far East Finance Centre, 16 Harcourt Road, Hong Kong not later than 4:30 p.m. on November 22, 2023 for registration.
5. In case of joint Shareholders, the vote of the senior joint Shareholder who tenders a vote, whether in person or by proxy, will be accepted to the exclusion of the votes of the other joint Shareholder(s) and for this purpose, seniority will be determined by the order in which the names stand in the register of members of the Company in respect of the joint shareholding.
6. Shareholders who attend the meeting in person or by proxy shall bear their own travelling and accommodation expenses.
7. A Shareholder or his/her proxy should produce proof of identity when attending the H Share Class Meeting.
8. Contact information of the meeting:

The Office of the Board of AIM Vaccine Co., Ltd.
Address: Room 218, 2/F, Xinghai Building, 16 Yingshun Road, Yinghai Town,
Daxing District, Beijing
Postal code: 100000
Phone: +86 10-8595 0621
Email: aim.securities@aimbio.com
9. Further details of the resolutions are set out in the circular of the Company dated November 10, 2023. Unless otherwise indicated, capitalized terms used in this notice shall have the same meanings as those defined in the circular.
10. References to dates and time in this notice are to Hong Kong dates and time.

As at the date of this notice, the Board of Directors of the Company comprises Mr. Yan ZHOU, Mr. Wen GUAN and Mr. Shaojun JIA as executive directors; Mr. Jie ZHOU, Mr. Xin ZHOU, Mr. Jichen ZHAO and Ms. Aijun WANG as non-executive directors; and Professor Ker Wei PEI, Mr. Xiaoguang GUO, Ms. Jie WEN and Mr. Hui OUYANG as independent non-executive directors.